Prognostic Significance of positive lymph node regression grade to Neoadjuvant Chemoradiation for Esophageal Squamous Cell Carcinoma

Author:

Zhou Yehan1,Liu Ying2,Guo Peng1,Huang Zongyao1,Zhou Chengmin1,Yang Hong1,Qin Sheng1,Zhu Jie1,Wang Yi1,Leng Xuefeng3,He Wenwu3,Wang Qifeng1,Liu Yang1

Affiliation:

1. Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China

2. Chengdu Medical College

3. Sichuan Cancer Hospital & Institute

Abstract

Abstract Background and Purpose To assess the relationship between metastatic lymph node (LN) responder status and recurrence-free survival (RFS) in patients undergoing neoadjuvant chemoradiotherapy (NCRT).Materials and Methods We retrospectively reviewed 304 patients with local advanced esophageal squamous cell carcinoma received NCRT followed by esophagectomy. For 112 patients with positive node, according to the proportion of residual viable tumor cells area within the whole tumor beds of all metastatic LNs, we classified LN-tumor regression grade (LN-TRG) into four categories: grade 1, 0%; 2, < 10%; 3, 10–50%; 4, > 50%. Patients with grade 1 LN-TRG of were considered LN responders, and those with grades 2–4, as LN nonresponders. Univariate and multivariate analyses of recurrence-free survival (RFS) were estimated by a Cox regression model, Kaplan-Meier curve, and log-rank test.Results The median follow-up time of a total of 112 patients was 29.6 months. 52 (46.4%) patients have experienced recurrence. In Cox univariate analysis, LN responder status, nerve invasion, and lymphovascular invasion significantly correlated with RFS. Multivariate analysis for RFS revealed that LN responder status (P < 0.05) was an independent prognostic factor. The 3-year RFS rates for patients with LN-TRG of 1 to 4 grades were 72.7%, 76.5%, 37.4%, and 28.5%, respectively, and the median RFS times were not reach, 43.56 months, 28.09 months, 22.77 months, respectively.Conclusions LN responder status is an independent prognostic factor for RFS in esophageal cancer patients who received NCRT.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3